Zhong Zheng Wang·2025-12-15 12:00Core Viewpoint - Fosun Pharma is investing 1.412 billion yuan to acquire a controlling stake in Green Valley Pharmaceutical, which focuses on the research, production, and sales of drugs for neurodegenerative diseases, particularly Alzheimer's disease [1][2]. Group 1: Investment Details - The acquisition will make Green Valley Pharmaceutical a subsidiary of Fosun Pharma [1]. - Green Valley's main product, Ganluo Sodium Capsule, received conditional approval from the National Medical Products Administration in November 2019 for treating mild to moderate Alzheimer's disease [1]. - The product is included in the national medical insurance directory as of 2021 [1]. Group 2: Financial Performance - In 2024, Green Valley is projected to achieve revenue of 572 million yuan and a pre-tax profit of 70.77 million yuan [2]. - From January to September 2025, Green Valley is expected to generate revenue of 102 million yuan but will incur a pre-tax loss of 67.61 million yuan due to the expiration of the original registration certificate [2]. Group 3: Strategic Focus - The investment is part of Fosun Pharma's strategy to enhance its presence in the central nervous system treatment sector, addressing unmet clinical needs in neurodegenerative diseases [3]. - The company plans to support the post-marketing confirmatory clinical trials for Ganluo Sodium Capsule to expedite its approval process [3]. - Fosun Pharma is also exploring a multi-technology approach to treatment solutions, including non-invasive diagnostic equipment and new oral drugs for Alzheimer's disease [3].